Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Inspire's dry eye product enters phase II testing

Jan. 10, 2000

Allergan's therapy for allergic conjunctivitis approved for U.S. marketing

Dec. 27, 1999

Milestone reached by Xoma in collaboration with Allergan

Dec. 27, 1999

Allergan expands ophthalmic allergy product portfolio

Dec. 21, 1999

Swiss regulatory authorities grant Visudyne Therapy its first approval

Dec. 20, 1999

Pharmos seeks approval for Loterox in the U.K.

Dec. 20, 1999

New to the U.K. market: ophthalmic steroid from Alcon causes less IOP elevation

Dec. 16, 1999

AEterna presents promising phase I data for AE-941 in AMD

Dec. 13, 1999

Cambridge NeuroScience and Allergan extend ophthalmic research collaboration

Dec. 9, 1999

Projected enrollment exceeded in Miravant's phase III AMD trials

Dec. 8, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...